natgillin/translations-raw huggingface dataset:
An indicating agent for evaluating mental conditions selected from the group consisting of mental fatigue, physical fatigue, stress, blue mood, comfortable mood, uncomfortable mood, dysthymia, compulsive, panic, anxiety, phobia, anthropophobia, social phobia, tension, working intensity, learning intensity, depression, schizophrenia, mental conditions similar to depression, mental conditions similar to schizophrenia and suicide risk, which comprises at least two kinds of factors selected from the group consisting of IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrophin 5, MCP-3, B-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF at a weighted composition ratio. 
Uporaba in vitro indikacijskog sredstva za vrednovanje mentalnih stanja, naznačena time, da su ta stanja odabrana iz skupine koju čine: mentalna iscrpljenost, fizička iscrpljenost, stres, anksioznost, depresija i shizofrenija, pri čemu indikacijsko sredstvo sadrži najmanje osam vrsta citokina odabranih iz skupine koju čine: IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, eotaksin, osnovni FGF, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrofin 5, MCP-3, B-2-mikroglobulin, angiotenzin II, CSF-3, CXC ligand kemokina l, CXC ligand kemokina 5 i HGF, gdje je količina svakog citokina pomnožena s koeficijentom faktora težine.
The system of claim 1, wherein the resid hydrocarbon fraction comprises hydrocarbons with a normal boiling point of at least 340° C. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da ostatak ugljikovodične frakcije sadržava ugljikovodike s uobičajenim vrelištem od najmanje 340 *C.
5A, 6). The method thus comprises a step of mutually positioning said loading form 11 and the loading members 31; this step of mutually positioning comprises the following steps: 
- uzajamnog stavljanja navedenog kalupa za punjenje (11) i navedenih naprava za punjenje (31), gdje se navedeni korak uzajamnog stavljanja sastoji u sljedećim koracima:
The method of claim 11, wherein 2-bromopropionic acid is reacted with an amine dissolved in DMF and bubbled until substitution is complete to form the N-substituted alanine residue. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što 2-brompropionska kiselina reagira s aminom otopljenum u DMI, te se propuhuje do završetka supstitucije kako bi se dobilo N-supstituirani alaninski ostatak.
Examples of said chemotherapeutic agents include alkylating agents, antimetabolites, cytotoxic antibiotics, adriamycin, dactinomycin, mitomycin, carminomycin, daunomycin, doxorubicin, tamoxifen, taxol, taxotere, vincristine, vinblastine, vinorelbine, etoposide (VP-16), 5-fluorouracil (5FU), cytosine arabinoside, cyclophosphamide, thiotepa, methotrexate, camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP), aminopterin, combretastatin(s), other vinca alkyloids and derivatives or prodrugs thereof. 
Oblik prema zahtjevu 33 ili 34, gdje se to kemoterapijsko sredstvo izabire između alkilirajućih sredstava, antimetabolita, citotoksičnih antibiotika, adriamicina, daktinomicina, mitomicina, karminomicina, daunomicina, doksorubicina, tamoksifena, taksola, taksoter, vinkristina, vinblastina, vinorelbina, etopozida (VP-16), 5- fluorouracila (5FU), citozin arabinozida, ciklofosfamida, tiotepa, metotreksata, kamptotecina, aktinomicina-D, mitomicina C, cisplatina (CDDP), aminopterina, kombretastatina, drugih vinka alkaloida, 1 njihovih derivata ili pro-lijekova.
As regards said calcium carbonate-comprising material in suspension, this material preferably consists of at least 50%, preferably of at least 80%, and more preferably of at least 98%, by weight of calcium carbonate relative to the total equivalent dry weight of said calcium carbonate-comprising material. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time što se materijal koji sadrži kalcijev karbonat sastoji od barem 50 %, poželjno barem 80 %, i poželjnije barem 98 %, težinski, kalcijevog karbonata u odnosu na ukupnu težinu tog materijala koji sadrži kalcijev karbonat.
The composition for the use according to any one of claims 1 to 4, wherein the anti-RSV immune response inducing composition that was administered to the female and the anti-RSV immune response inducing composition administered to the infant are not the same. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na ženi 1 pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na dojenčetu nisu isti.
The composition for use according to claim 10, wherein said depressive disorder is selected from major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression; premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar I disorder, bipolar II disorder and cyclothymic disorder. 
Pripravak sukladno patentnom zahtjevu 10, naznačeno time, da je navedeni depresivni poremećaj odabran 17 većeg depresivnog poremećaja, kronične depresije, ozbiljnih unipolarnih periodičnih većih depresivnih epizoda, distimijskog poremećaja, depresivne neuroze i neurotske depresije, melankolične depresije, atipične depresije, reaktivne depresije, depresije otporne na liječenje, sezonskog afektivnog poremećaja 1 pedijatrijske depresije; predmenstrualnog sindroma, predmenstrualnog disforičnog poremećaja, valunga, bipolarnog poremećaja ili manične depresije, bipolarnog poremećaja tip I, bipolarnog poremećaja tip II 1 ciklotimnog poremećaja.
The apparatus of claim 1, wherein a scan pattern for scanning flags indicating whether each transform coefficient of each sub-block is 0 or not is the same as the scan pattern for scanning the non-zero coefficients of each sub-block. 
Uređaj prema zahtjevu 1, naznačen time da obrazac skeniranja za skeniranje zastavica označava je li odgovarajući koeficijent transformacije 0 ili ne isti kao obrazac skeniranja za skeniranje ne-nultih koeficijenata svakog podbloka.
contacting the acid solvate of the compound of formula II with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and contacting the amide solvate of the compound of formula II with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. In a particular embodiment, the compound of formula I produced by this method is a hydrate, such as a hexahydrate. 
H m OR OH OH II kontaktiranje kiselog solvata spoja s formulom II s amidom u pod uvjetima pogodnim za tvorbu amidnog solvata spoja s formulom II; 1 kontaktiranje amidnog solvata spoja s formulom II s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za tvorbu spoja s formulom I.
The solvent was removed under reduced pressure and the solids were re-suspended in ethyl acetate (500 mL) and NaHCO3 (sat.) 
Otapalo se ukloni pri sniženom tlaku i krutina se resuspendira u etilnom acetatu (500 ml) i NaHCO; (zas).
Cell Culture Process Equipment All experiments were performed with systems composed of a bioreactor connected to an external column The configuration of the bioreactors was similar to the configuration of 40 liters Free-Standing Laboratory bioreactors manufactured by New MBR. 
Svi eksperimenti su provedeni sa sustavom koji obuhvaća bioreaktor koji je povezan na vanjsku kolnu. Konfiguracija bioreaktora je slična konfiguraciji bioreaktora od 40 litara tipa Free-Standing Laboratry, proizvedeni u New MBR.
The method according to clause 3, wherein the planar wooden core is formed by cross-laminated timber. 
Postupak sukladno zahtjevu 3, pri čemu je planarna drvena jezgra (41, 46) formirana poprečno laminiranim drvetom.
Stereoisomeric mixtures, e.g., mixtures of diastereomers, can be separated into their corresponding isomers in a manner known per se by means of suitable separation methods. 
Stereoizomerne smjese, npr. smjese diastereomera, mogu se rastaviti na njihove odgovarajuće izomere na način koji je kao takav poznat pomoću prikladnih postupaka rastavljanja.
said gear mechanism (6 a) constitutes a first gear mechanism of the suspension device (1): 
- = navedeni mehanizam zupčanika (6a) predstavlja prvi stupanj prijenosa naprave za vješanje (1);
If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose and thickening agent. 
Ako se želi, ovakve tekuće kompozicije mogu sadržavati sredstva za bojenje, sredstva za ukus, saharin i karboksimetil celulozu i sredstvo za zgušnjavanje.
heating the chamber thereby vaporising the ethanol sample producing fumes which pass over the dehydration catalyst, dehydrating ethanol by removing exchangeable hydrogen and forming ethene; 
- zagrijavanje komore čime se vaporizira uzorak etanola te proizvode pare koje prelaze preko katalizatora za dehidraciju, dehidrirajući etanol uklanjanjem izmjenjivog vodika i formiranjem etilena;
A platform (1) according to at least one of the preceding claims, in which at least the bottom plane (2) and the sidewalls (3, 4) are made of aluminum and/or of a product consisting of aluminum and of a material which is at most as heavy as aluminum. 
Platforma (1) u skladu sa najmanje jednim od prethodnih patentnih zahtjeva, u kojoj su najmanje donja ravnina (2) 1 bočni zidovi (3, 4) napravljeni od aluminija i/ili od proizvoda koji se sastoje od aluminija i od materijala koji je najviše iste težine kao aluminij.
wherein at least two of said nucleic acid molecules are provided with means for preferential pairing of said 1st and 2nd CH3 domain-comprising polypeptides and said 3rd and 4th CH3-domain comprising polypeptides, said method further comprising the step of culturing said host cell and allowing for expression of said at least four nucleic acid molecules and harvesting said at least two different Ig-like molecules from the culture. 
četvrte molekule nukleinske kiseline koja kodira četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni postupak dalje sadrži korak kultivacije navedene stanice domaćina i omogućavanja ekspresije navedena najmanje četiri molekule nukleinske kiseline i sakupljanja navedena najmanje dva različita antitijela iz kulture.
The process of claim 9, wherein the temperature of the dehydrochlorination reaction zone is from 120 to 180 °C the pressure of the separation zone is in the range from 13 to 80 kPa (100 to 600 torr) and the temperature of the condensing zone is such as to cause 1,1,2,3-tetrachloropropene distilled from the reaction zone to condense into liquid. 
Postupak iz patentnog zahtjeva 9, pri čemu zona razdvajanja obuhvaća praznu cijev ili cijev koja sadrži pakiranje ili drugu strukturu pogodnu za poticanje dodirivanja pare i tekućine i kondenzacijsku zonu koja obuhvaća posudu pogodnu za uzrokovanje kondenzacije u tekući oblik nekih od sastavnica toka klorovodika, kao što je 1,1,3-trikloropropen ili ugljikov tetraklorid.
Following administration of a compound of formula I during phase I clinical trials odour related adverse events were observed. 
Nakon primjene spoja formule I tijekom faze I kliničkih ispitivanja, primijećene su nuspojave povezane s mirisom.
0.5% The formulation was prepared by using a suitable closed vessel provided with a stirrer. 
0,5% Formulacija je pripremljena koristeći odgovarajuću zatvorenu posudu s mješalicom.
As is known, one-component polyurethane adhesives are applied as a single product, whereby the adhesive cures to a water insoluble resin by means of its content of isocyanate groups which react with the wood humidity and/or other polar groups being contained in the wood. 
Kao što je poznato, jedno-komponenina poliuretanska ljepila se nanose kao samo jedan proizvod, pri čemu se ljepilo pretvara u smolu koja je netopiva u vodi uz pomoć sadržaja skupine izocianata koji se nalazi u njoj i koji reagira s vlagom iz drva i/ili s drugim polarnim skupinama koje su sadržane u drvu.
The antibody or antibody fragment which binds to human PD-1 of claim 1, wherein said antibody or antibody fragment blocks binding of human PD-L1 and/or human PD-L2 to human PD-1 with an IC50 of about 1 nM or lower. 
Antitijelo ili fragment antitijela prema patentnom zahijevu 1, naznačen time što navedeno antitijelo ili fragment antitijela blokira vezanje humanog PD-L1 i/ili humanog PD-L2 za humani PD-1 sa ICs9 od oko 1 nM ili niže.
The solid oral pharmaceutical formulation of claim 1, wherein the formulation is selected from the group consisting of: 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je formulacija kapsula odabrana iz skupine koja sadrži:
150 mL of water were added. 
Doda se 150 mL vode.
The so obtained ink was applied in the form of a patch onto standard security paper (100 g/m2) and the imprinted paper was further processed as described in example 1. 
Tinta dobivena na takav način se nanosi u obliku otisnute površine na standardni sigurnosni papir (100 g/m'), a otisnuti papir sc dodatno obrađuje na način opisan u primjeru 1.
A dsRNA of any one of claims 1 to 7 for use in a method of treatment of a disorder mediated by TTR expression in a human. 
dsRNA prema zahtjevima 1 do 8, naznačena time da je za uporabu kod liječenja čovjeka s poremećajem posredovanim s ekspresijom TTR, pri čemu
The pharmaceutical composition of clause 47, further comprising a solvent, diluent, excipient, carrier, or solubilizing agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži otapalo, razrjeđivač, pomoćnu tvar, podlogu ili solubilizacijsko sredstvo.
The pre-nozzle according to claim 1, characterized in that the water inlet opening area of the pre-nozzle is bent or curved and in particular is formed over at least two planes, which are at an angle to one another, wherein the angle is greater than 90° and smaller than 180°. 
Pred-mlaznica prema bilo kojem od prethodnih zahtjeva, okarakterizirana time da je ulazni prostor (19) sa strane otvora za vodu pred-mlaznice (10a, 10b, 10c) formiran preko najmanje dvije ravnine, koje su pod kutom (36) jedna prijema drugoj, pri čemu je kut (36) veći od 90" i manji od 180".
Figure 8 is a perspective view of an exemplary embodiment of a blender container; 
Slika 8 = je prikaz primjera ostvarenja posude mješalice;
A process according to claim 2 wherein the equivalent ratio is in the range of 1.1 to 1.5. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da je odgovarajući omjer u rasponu od 1.1 do 1.5.
Nanoparticle or nanoparticles' aggregate for use in altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide selected from the group consisting of CeO2, Tm2O3, HfO2, WO3, and PdO, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7,1 g/cm3 when the metal oxide is CeO2, of at least 8,3 g/cm3 when the metal oxide is Tm2O3, of at least 7,4 g/cm3 when the metal oxide is HfO2, of at least 7,2 g/cm3 when the metal oxide is WO3, and of at least 7,9 g/cm3 when the metal oxide is PdO, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Nanočestica ili agregat nanočestica za uporabu u mijenjanju ili uništavanju ciljnih stanica u životinje kada se te stanice izlože ionizirajućim zračenjima, pri čemu se svaka nanočestica ili agregat nanočestica sastoji od metalnog oksida odabranog iz skupine koju čine CeO2, Tm2O3, HfO2, WO3 i PdO, gdje je gustoća te nanočestice ili agregata nanočestica najmanje 7,1 g/cm3 ako je metalni oksid CeO2, najmanje 8,3 g/cm3 ako je metalni oksid Tm2O3, najmanje 7,4 g/cm3 ako je metalni oksid HfO2, najmanje 7,2 g/cm3 ako je metalni oksid WO3, i najmanje 7,9 g/cm3 ako je metalni oksid PdO, i gdje je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6.5 i 7.5 u fiziološkoj tekućini.
The method according to claim 25, wherein following addition of 2-((1-methylpropyl)amino)ethanol to the suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
HR P20161356 T1 19.Postupak u skladu s patentnim zahtjevom 17, naznačen time da nakon dodavanja navedenog 2-((1- metilpropil)aminojetanola u navedenu suspenziju, suspenzija prolazi kroz prolaz koji ima protok otopine reguliran kao funkciju vodljivosti suspenzije.
reacting a compound of Formula IIIc: a reagent of formula R1MgY, followed by reacting with a compound of formula B(OR2)3 to form a compound of Formula IIId: 
X llc reagensa s formulom R,MgY, nakon čega slijedi reakcija sa spojem s formulom B(OR>); da se dobije spoj s formulom IIId: m
Freezing time to −48° C.: 
Vrijeme zamrzavanja do - 4h
Compound according to claim 1 wherein R1 and R3 are independently selected from the group consisting of C1-4alkoxy, C1-4alkylcarbonyloxy and benzyloxy 
Spoj u skladu s patentnim zahtjevom 1 naznačen time što se R2 i R4 neovisno bira iz skupine koju čine vodik, halogen, trifluormetil i C1-4alkoksi.
An isolated nucleic acid molecule encoding at least one isolated IL-23p19 antibody according to any of claims 1-7 and 10-14. 
Izolirana molekula nukleinske kiseline koja kodira najmanje jedno izolirano IL-23p19 antitijelo prema bilo kojem od patentnih zahtijeva 1-7 1 10-14.
The method of item 5, wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, talc, sucrose fatty acid ester, sodium stearyl fumarate, and hydrogenated oil. 
Postupak prema zahtjevu 5, naznačen time što je sredstvo za povećanje skliskosti odabrano iz skupine koju čine magnezijev stearat, kalcijev stearat, talk, saharozni ester masne kiseline, natrijev stearil fumarat, i hidrogenirano ulje.
A method according to claim 1, wherein the sludge treatment with said superheated steam is performed with a steam-treatment apparatus which comprises at least one steam-treatment unit arranged to use superheated steam and into which the material to be treated is brought. 
12.Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 11, karakterizirana tretiranjem mulja superzagrijanom parom koje se izvodi u uređaju za tretiranje parom koji sadrži barem jednu jedinicu za tretiranje parom postavljenu za korištenje superzagrijane pare i u koju se unosi material koji treba tretirati.
A peptide consisting of a sequence that is selected from the group of SEQ ID No. 4 and SEQ ID No. 5. 
Peptid izabran iz peptida koji se sastoji od sekvence u skladu s SEQ ID br. 14,
In yet another embodiment, the present application discloses pharmaceutical compositions comprising a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, and a pharmaceutically acceptable carrier or excipient. 
Farmaceutska kompozicija koja sadrži spoj bilo kojeg patentnog zahtjeva od 1 do 8, ili njegove farmaceutski prihvatljive soli, solvate, i/ili estere, 1 farmaceutski prihvatljiv nosač ili ekscipijens.
The system of claim 5 further comprising a reader apparatus (410) for detecting the identification tag (320). 
Sustav u skladu s patentnim zahtjevom 5, naznačen time što dodatno sadrži uređaj za očitavanje (410), namijenjen detektiranju identifikacijskog biljega (320).
A process to make a sourdough from a microencapsulated bacterial consortium of claim 1, in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin, comprising the following steps: 
Postupak proizvodnje kiselog tijesta iz mikroenkapsuliranog bakterijskog konzorcija prema zahtjevu 1, u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla, koji sadrži sljedeće korake: i)
A process as in Claim 1, wherein R1 is cyclobutyl, m is 1 and R2 is selected from the group consisting of 4-fluorophenyl, 3-cyanophenyl, 4-tetrahydropyranyl, LG1 is chloro and LG2 is chloro. 
Postupak prema zahtjevu 1, naznačen time da je R1 ciklobutil, m je 2 i R2 je odabran iz skupine koja se sastoji od 4-fluorofenila, 3-cijanofenila, 4-tetrahidropiranila, LG1 je kloro i LG2 je kloro.
Various forms of prodrugs are well known in the art. 
Različiti oblici prolijekova su dobro poznati u tehnici.
A truncated PH20 hyaluronidase that consists of the sequence of amino acid residues 36-469, 36-470 or 36-471 of SEQ ID NO:107. 
EsPH20 prema zahtjevu 1 koji se sastoji od sekvence amino kiselina prikazanih kao amino kiseline 36-495, 36-496, 36-497, 36-498, 36-499 ili 36-500 od SEQ ID NO: 107.
A spray dispenser according to claim 6, wherein the dispenser assembly comprises the sealing member (107). 
Raspršivač sukladno zahtjevu 6, pri čemu sklop za točenje sadrži element za brtvljenje (107).
The system of claim 19 wherein said non-varying direct current for spinal stimulation ranges from about 2 mA to about 4 or 5 mA. 
Sustav sukladno zahtjevu 1 pri čemu je navedena istosmjerna struja za spinalnu stimulaciju opsega od otprilke 2 ma do otprilike SmA za terapiju mišićnog tonusa kod ljudi.
The hydroboration-oxidation-hydrolysis sequence of reactions of Process A typically provides dihydrotetrabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a trans relative orientation. 
Hidroboriranje-oksidacija-hidroliza redoslijed reakcija Postupka A obično daje izomere dihidrotetrabenazina u kojima vodikovi atomi u položajima 2- i 3- imaju frans relativnu orijentaciju.
The protected product was purified on a reverse phase semi-prep scale HPLC before running the TBAF deprotection method, as shown in Figure 27, to remove the TBDMS group to form Formula 22 (where R1=R2=Ph; R7=CH3; R8=R9=H in generalized formula O of Scheme 6). 
Zaštićeni produkt je bio očišćen pomoću reverzne faze polu-preparativne skale na stupcu HPLC prije pokretanja postupka za TBAF zaštitu, kao što je prikazano na slici 27, da HR P20080057 T3 bi se uklonila skupina TBDMS radi dobivanja formule 22 (gdje Ri=R2=Ph; R;=CH;; Rg-Ro=H u općoj formuli O iz sheme 6).
L-aspartic acid forms a 1:1 acid addition salt with 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine which is used in the present invention. 
10. Sol prema zahtjevu 7, pri čemu je to adicijska sol L-asparaginske kiseline 4-[2-(4- metilfenilsulfanil)fenil] piperidina.
first hinging means (71) ensure a direct connection of an end zone of the bars, or alternatively of one of the parallel sides of the polygonal plate, to first members (45B) of the load bearing structure; 
- prva šarka (71) osigurava izravnu vezu krajnjeg dijela štapova, ili pak jedne od paralelnih strana poligonalne ploče, s prvim elementima (45B) nosive strukture;
The mouse of claim 1, wherein the mouse is from a strain selected from the group consisting of a 129 strain, a C57BL/6 strain, and a mixed 129xC57BL/6 strain. The mouse of claim 11, wherein the mouse is 50% 129 and 50% C57BL/6. 
miš je soj odabran iz grupe koja se sastoji od soja 129, soja C57BL/6 i mješovitog soja 129 x C57BL/6, poželjno naznačen time, što je miš 50 % soj 129 i 50 % soj C57BL/6.
a sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of a heavy chain variable domain sequence of H5; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji hibridizira pod umjereno strogim uvjetima s komplementarnim polinukleotidom koji se sastoji od SEQ ID NO:360;